According to a press release from Zealand Pharma, the company licensing the drug to Boehringer, the abstract was "unintentionally and temporarily made available through the congress website." It has since been removed.
The topline data from the double-blind trial was announced earlier this year, demonstating that 83% of adults treated with survodutide achieved groundbreaking results in liver disease due to MASH, with significant improvements in liver fibrosis (scarring).
According to Zealand, the new results in the abstract include a key secondary endpoint of improvement in fibrosis without worsening of MASH, confirming "highly statistically significant reductions in fibrosis with survodutide.